

THRU E-MAIL

April 1, 2025

The Secretary
BSE Ltd.
Phiroze Jeejeebhoy Towers
27th Floor, Dalal Street
Mumbai 400 023
corp.relations@bseindia.com

The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Flr, Plot # C/1
G Block, Bandra-Kurla Complex,
Bandra (E), Mumbai 400 051
takeover@nse.co.in

Dear Sir,

Re: Declaration under Regulation 31 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 - Krebs Biochemicals & Industries Ltd.-
(Scrip code: BSE: 524518 and NSE: KREBSBIO)

Pursuant to Regulation 31 (4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, we as promoters of Krebs Biochemicals & Industries Ltd. hereby declare that we have not made any encumbrance, directly or indirectly, on the equity shares held by us in Krebs Biochemicals & Industries Ltd.

Kindly acknowledge the receipt.

Thanking you

Yours faithfully
For Ipca Laboratories Limited



Harish Kamath
Corporate Counsel & Company Secretary

Cc: 1. Krebs Biochemicals and Industries Limited
Kothapalli (V), Kasimkota (M)
Anakapalli, Vishakapatnam (D)
Andhra Pradesh – 531 031
com_sec@krebsbiochem.com

2. Audit Committee of Board of Directors of Krebs Biochemical & Industries Ltd..

Ipca Laboratories Ltd.
www.ipca.com